Adicet Bio, Inc.
Adicet Bio is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. It discovers and develops allogeneic gamma delta T cell therapies for patients with autoimmune diseases and cancer. Its manufacturing process uses cells from unrelated donors to produce therapies designed to be stored and sold on demand. Adicet Bio’s lead candidate, prulacabtagene leucel, or prula-cel, is in Phase 1 clinical development for multiple autoimmune diseases. The company is also developing ADI-212, a gene-edited candidate designed to target prostate-specific membrane antigen, and has additional research and preclinical programs for autoimmune diseases, hematological malignancies and solid tumors. It has licensing and collaboration agreements with other organizations, including Regeneron and CRISPR Therapeutics.
No SEC Form 4 filings for $ACET in the last 30 days.
See all $ACET insider activity →Adicet Bio director Andrew Sinclair resigned from the board and committees. Michael Grissinger was appointed to the Audit Committee and named chair of the Nominating and Corporate Governance Committee, effective November 13, 2026. The changes were not related to disagreements with management or company operations.
Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors. On November 11, 2026, Andrew Sinclair, Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board, the A
Guggenheim kept Adicet Bio's rating at Buy but reduced its price target to $55 from $90, a 38.9% cut. This implies a 1783.6% upside from the Nov 5 close of $2.92, according to the firm.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ACET (Adicet Bio, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ACET coverage spans financial news, technology and earnings.
Board change may cause slight investor uncertainty.
Minor governance change with limited market impact.
Guggenheim kept Adicet Bio's rating at Buy but reduced its price target to $55 from $90, a 38.9% cut. This implies a 1783.6% upside from the Nov 5 close of $2.92, according to the firm.
Earnings miss likely triggers sell pressure.
Positive Phase 1 safety/efficacy data and a net loss of $18.9 M were disclosed.
AlphAI scores every news story that mentions ACET with an AI model for sentiment and relevance, and aggregates insider trades from Adicet Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Adicet Bio director Andrew Sinclair resigned from the board and committees. Michael Grissinger was appointed to the Audit Committee and named chair of the Nominating and Corporate Governance Committee, effective November 13, 2026. The changes were not related to disagreements with management or company operations.
Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors. On November 11, 2026, Andrew Sinclair, Ph.D., a Class III member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board, the A
Guggenheim kept Adicet Bio's rating at Buy but reduced its price target to $55 from $90, a 38.9% cut. This implies a 1783.6% upside from the Nov 5 close of $2.92, according to the firm.
Adicet Bio (ACET) reported Q3 GAAP EPS of -$1.76, missing estimates by $0.17. The company had $100.9M in cash and equivalents as of September 30, 2026, and expects this to be sufficient.
Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Results of Operations and Financial Condition. Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates Phase 1 data for prulacabtagene leucel (prula-cel, formerly ADI-001) demonstrated durable responses and a favorable safety profile in patients with systemic lupus erythematosus (SLE) with or wit
Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Other Events. Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis - Prula-cel shown to be generally well tolerated with no CRS greater than Grade 2 and no IEC-HS or ICANS -
Adicet Bio (ACET) will present clinical data for prula-cel, a potential lupus treatment, on September 28, 2026. The Phase 1 study results will be discussed in a webcast. Adicet focuses on developing allogeneic CAR-T therapies for autoimmune diseases and cancers.
Adicet Bio (ACET) released a September 2026 investor presentation, outlining clinical progress for prula-cel and ADI-212. Prula-cel is advancing toward a registrational pathway for LN/SLE, with pivotal data expected in the coming years. ADI-212 has received IND clearance for mCRPC, with clinical enrollment planned for 4Q 2026 and data expected in 1H/2H 2027. Initial clinical data for prula-cel showed clinical activity and favorable safety signals.
Adicet Bio completed the last patient visit for its Phase 1 prula-cel study in SLE, with topline data expected in September 2026. The FDA cleared the IND for ADI-212 in mCRPC, with Phase 1 enrollment starting in 4Q 2026. The company also announced progress on its in vivo CAR-T platform, with the first candidate expected to enter clinical trials in 2H 2027, according to the company.
Adicet Bio received FDA clearance to start a Phase 1 trial for ADI-212, an experimental cell therapy for advanced prostate cancer. The company plans to enroll patients in the final quarter of 2026. ADI-212 is an off-the-shelf therapy designed to target PSMA protein on prostate-cancer cells, with added modifications to enhance effectiveness against solid tumors.
